Paper Details

  1. Home
  2. Paper Details

Systemic Targeted Treatments for Basal Cell Carcinoma.

Author: JohnsonNathan M, PhillipsMariana A, SvobodaSteven A

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Vismodegib and sonidegib are two drugs that target the sonic hedgehog (SHH) pathway, which can cause certain types of skin cancer. These drugs are effective in treating basal cell carcinoma (BCC), but they can also cause side effects that may lead to treatment discontinuation.
Paper Details　
Original Abstract of the Article :
The sonic hedgehog (SHH) inhibitors vismodegib and sonidegib are the only 2 first-line systemic medications approved for the treatment of locally aggressive basal cell carcinoma (BCC). Vismodegib is the only SHH inhibitor approved for metastatic BCC. Cemiplimab, an immune checkpoint inhibitor (ICI),...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.12788/cutis.0560

データ提供：米国国立医学図書館（NLM）

Systemic Targeted Treatments for Basal Cell Carcinoma

[Basal cell carcinoma] (BCC) is a common type of skin cancer. This study focuses on the current landscape of systemic treatments for locally aggressive and metastatic BCC. The researchers review the efficacy and safety of [sonic hedgehog] (SHH) inhibitors such as [vismodegib] and [sonidegib], as well as the [immune checkpoint inhibitor] [cemiplimab] for treating advanced BCC.

Exploring New Options for Treating Advanced BCC

The study provides a comprehensive overview of the current systemic treatment options for advanced BCC. The researchers highlight the efficacy of SHH inhibitors in treating locally aggressive and metastatic BCC, as well as the emerging role of immune checkpoint inhibitors in this setting. The review also addresses the common adverse effects associated with these therapies.

Hope for a More Effective and Personalized Approach

This study emphasizes the ongoing progress in developing new and more effective treatments for BCC. Like a camel adapting to the changing landscape of the desert, researchers are exploring new pathways to target this common cancer. This research highlights the potential for personalized treatment strategies that utilize a combination of therapies to optimize patient outcomes.

Dr. Camel's Conclusion

This study offers a glimpse into the exciting future of BCC treatment. Like a camel discovering a hidden oasis in the desert, researchers are uncovering new ways to combat this common cancer. The study's insights into the efficacy and safety of novel therapies provide hope for a more effective and personalized approach to treating BCC.
Date :
  1. Date Completed 2022-08-16
  2. Date Revised 2022-08-16
Further Info :

Pubmed ID

35960978

DOI: Digital Object Identifier

10.12788/cutis.0560

Related Literature

Article Analysis
・Side Effects of sonidegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.